A lack of understanding still exists when assessing the full efficacy and safety of dupilumab for the treatment of atopic dermatitis, especially because the only data available is confined to strict, randomized controlled trials (RCTs). Will real-world results yield varied results from the RCTs?
Learn more at the Journal of the American Academy of Dermatology.